Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Clin Hypertens (Greenwich) ; 21(9): 1335-1342, 2019 09.
Article in English | MEDLINE | ID: mdl-31389662

ABSTRACT

Pediatric elevated blood pressure (BP) and hypertension are usually defined using traditional BP tables at the 90th and 95th percentiles, respectively, based on sex, age, and height, which are cumbersome to use in clinical practice. The authors aimed to assess the performance of the static cut-points (120/80 mm Hg and 130/80 mm Hg for defining elevated BP and hypertension for adolescents, respectively; and 110/70 mm Hg and 120/80 mm Hg for children, respectively) in predicting increased arterial stiffness. Using data from five population-based cross-sectional studies conducted in Brazil, China, Korea, and New Zealand, a total of 2546 children and adolescents aged 6-17 years were included. Increased arterial stiffness was defined as pulse wave velocity ≥sex-specific, age-specific, and study population-specific 90th percentile. Compared to youth with normal BP, those with hypertension defined using the 2017 American Academy of Pediatrics guideline (hereafter referred to as "percentile-based cut-points") and the static cut-points were at similar risk of increased arterial stiffness, with odds ratios and 95% confidence intervals of 2.35 (1.74-3.17) and 3.07 (2.20-4.28), respectively. Area under the receiver operating characteristic curve and net reclassification improvement methods confirmed the similar performance of static cut-points and percentile-based cut-points (P for difference > .05). In conclusion, the static cut-points performed similarly well when compared with the percentile-based cut-points in predicting childhood increased arterial stiffness. Use of static cut-points to define hypertension in childhood might simplify identification of children with abnormal BP in clinical practice.


Subject(s)
Hypertension/physiopathology , Pulse Wave Analysis/methods , Vascular Stiffness/physiology , Adolescent , Blood Pressure/physiology , Blood Pressure Determination/methods , Brazil/epidemiology , Case-Control Studies , Child , China/epidemiology , Cross-Sectional Studies , Female , Humans , Hypertension/diagnosis , Male , New Zealand/epidemiology , Republic of Korea/epidemiology , Risk Factors
2.
Addiction ; 114(6): 1060-1073, 2019 06.
Article in English | MEDLINE | ID: mdl-30681215

ABSTRACT

AIMS: This paper presents updated prevalence estimates of awareness, ever-use, and current use of nicotine vaping products (NVPs) from 14 International Tobacco Control Policy Evaluation Project (ITC Project) countries that have varying regulations governing NVP sales and marketing. DESIGN, SETTING, PARTICIPANTS AND MEASUREMENTS: A cross-sectional analysis of adult (≥ 18 years) current smokers and ex-smokers from 14 countries participating in the ITC Project. Data from the most recent survey questionnaire for each country were included, which spanned the period 2013-17. Countries were categorized into four groups based on regulations governing NVP sales and marketing (allowable or not), and level of enforcement (strict or weak where NVPs are not permitted to be sold): (1) most restrictive policies (MRPs), not legal to be sold or marketed with strict enforcement: Australia, Brazil, Uruguay; (2) restrictive policies (RPs), not approved for sale or marketing with weak enforcement: Canada, Malaysia, Mexico, New Zealand; (3) less restrictive policies (LRPs), legal to be sold and marketed with regulations: England, the Netherlands, Republic of Korea, United States; and (4) no regulatory policies (NRPs), Bangladesh, China, Zambia. Countries were also grouped by World Bank Income Classifications. Country-specific weighted logistic regression models estimated adjusted NVP prevalence estimates for: awareness, ever/current use, and frequency of use (daily versus non-daily). FINDINGS: NVP awareness and use were lowest in NRP countries. Generally, ever- and current use of NVPs were lower in MRP countries (ever-use = 7.1-48.9%; current use = 0.3-3.5%) relative to LRP countries (ever-use = 38.9-66.6%; current use = 5.5-17.2%) and RP countries (ever-use = 10.0-62.4%; current use = 1.4-15.5%). NVP use was highest among high-income countries, followed by upper-middle-income countries, and then by lower-middle-income countries. CONCLUSIONS: With a few exceptions, awareness and use of nicotine vaping products varied by the strength of national regulations governing nicotine vaping product sales/marketing, and by country income. In countries with no regulatory policies, use rates were very low, suggesting that there was little availability, marketing and/or interest in nicotine vaping products in these countries where smoking populations are predominantly poorer. The higher awareness and use of nicotine vaping products in high income countries with moderately (e.g. Canada, New Zealand) and less (e.g. England, United States) restrictive policies, is likely due to the greater availability and affordability of nicotine vaping products.


Subject(s)
Commerce/legislation & jurisprudence , Electronic Nicotine Delivery Systems , Ex-Smokers/statistics & numerical data , Health Knowledge, Attitudes, Practice , Public Policy/legislation & jurisprudence , Smokers/statistics & numerical data , Vaping/epidemiology , Adult , Australia/epidemiology , Bangladesh/epidemiology , Brazil/epidemiology , Canada/epidemiology , China/epidemiology , Cross-Sectional Studies , England/epidemiology , Female , Humans , Logistic Models , Malaysia/epidemiology , Male , Marketing/legislation & jurisprudence , Mexico/epidemiology , Middle Aged , Netherlands/epidemiology , New Zealand/epidemiology , Prevalence , Republic of Korea/epidemiology , United States/epidemiology , Uruguay/epidemiology , Zambia/epidemiology
3.
An Bras Dermatol ; 93(1): 111-113, 2018.
Article in English | MEDLINE | ID: mdl-29641709

ABSTRACT

Primary cutaneous amyloidosis is limited to the skin without involving any other tissue. Nodular amyloidosis is rare, and atrophic nodular cutaneous amyloidosis is even rarer. We describe the fourth case of atrophic nodular cutaneous amyloidosis by searching PubMed databases. A 52-year-old female presented to our hospital with a 2-year history of orange papules and nodules without subjective symptom on her right abdomen. Review of systems was negative. Atrophic nodular amyloidosis may progress to primary systemic disease in up to 7% of cases. Because our patient had no systemic involvement, she was diagnosed with atrophic nodular cutaneous amyloidosis based on characteristic symptoms and histopathologic examination. Routine follow-up for this patient is necessary to detect any potential disease progression.


Subject(s)
Amyloidosis/pathology , Skin Diseases/pathology , Abdominal Wall/pathology , Amyloidosis/diagnosis , Atrophy/pathology , Female , Humans , Middle Aged , Skin Diseases/diagnosis
4.
An. bras. dermatol ; An. bras. dermatol;93(1): 111-113, Jan.-Feb. 2018. tab, graf
Article in English | LILACS | ID: biblio-887138

ABSTRACT

Abstract: Primary cutaneous amyloidosis is limited to the skin without involving any other tissue. Nodular amyloidosis is rare, and atrophic nodular cutaneous amyloidosis is even rarer. We describe the fourth case of atrophic nodular cutaneous amyloidosis by searching PubMed databases. A 52-year-old female presented to our hospital with a 2-year history of orange papules and nodules without subjective symptom on her right abdomen. Review of systems was negative. Atrophic nodular amyloidosis may progress to primary systemic disease in up to 7% of cases. Because our patient had no systemic involvement, she was diagnosed with atrophic nodular cutaneous amyloidosis based on characteristic symptoms and histopathologic examination. Routine follow-up for this patient is necessary to detect any potential disease progression.


Subject(s)
Humans , Female , Middle Aged , Skin Diseases/pathology , Amyloidosis/pathology , Atrophy/pathology , Skin Diseases/diagnosis , Abdominal Wall/pathology , Amyloidosis/diagnosis
5.
J Pediatr ; 158(2): 234-8.e1, 2011 Feb.
Article in English | MEDLINE | ID: mdl-20850766

ABSTRACT

OBJECTIVE: To assess the genetic contribution to late-onset sepsis in twins in the newborn intensive care unit. STUDY DESIGN: A retrospective cohort analysis of twins born from 1994 to 2009 was performed on data collected from the newborn intensive care units at Yale University and the University of Connecticut. Sepsis concordance rates were compared between monozygotic and dizygotic twins. Mixed-effects logistic regression analysis was performed to determine the impact of selected nongenetic factors on late-onset sepsis. The influence of additive genetic and common and residual environmental effects were analyzed and quantified. RESULTS: One hundred seventy monozygotic and 665 dizygotic twin pairs were analyzed, and sepsis identified in 8.9%. Mean gestational age and birth weight of the cohort was 31.1 weeks and 1637 grams, respectively. Mixed-effects logistic regression determined birth weight (regression coefficient, -0.001; 95% CI, -0.003 to 0.000; P = .028), respiratory distress syndrome (regression coefficient, 1.769; 95% CI, 0.943 to 2.596; P < .001), and duration of total parenteral nutrition (regression coefficient, 0.041; 95% CI, 0.017 to 0.064; P < .001) as significant nongenetic factors. Further analysis determined 49.0% (P = .002) of the variance in liability to late-onset sepsis was due to genetic factors alone, and 51.0% (P = .001) the result of residual environmental factors. CONCLUSIONS: Our data support significant genetic susceptibility to late-onset sepsis in the newborn intensive care unit population.


Subject(s)
Blood-Borne Pathogens/isolation & purification , Cross Infection/genetics , Environmental Exposure/adverse effects , Genetic Predisposition to Disease/epidemiology , Sepsis/genetics , Twins , Age of Onset , Birth Weight , Cohort Studies , Confidence Intervals , Cross Infection/epidemiology , Female , Hospital Mortality/trends , Humans , Infant, Newborn , Intensive Care Units, Neonatal , Logistic Models , Male , Prognosis , Retrospective Studies , Sepsis/epidemiology , Survival Rate , Time Factors , Twins, Dizygotic/genetics , Twins, Monozygotic/genetics
SELECTION OF CITATIONS
SEARCH DETAIL